Some AMLs develop secondary to MDS, and these occur in patients with acquired mutations in genes encoding for myeloid transcription factors (RUNX1, CEBPA) or signal transduction proteins (FLT3) [9]. The gene discussed is FLT3; the disease is myelodysplastic syndrome.